Human EG-VEGF/PK1 Antibody Summary
Ala20-Phe105
Accession # P58294
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: EG-VEGF/PK1
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF), also called prokineticin 1 (PK1), is a member of the prokineticin family of secreted proteins that share a common structural motif containing ten conserved cysteine residues that form five pairs of disulfide bonds (1, 2). Members of this family include the mammalian EG-VEGF/PK1 and PK2, as well as the venom protein A (VPRA) from the venom of black mamba snake and the frog Bombina variegata, Bv8 (1). Human EG-VEGF precursor is a 105 amino acid (aa) residue protein with a 19 aa signal peptide that is cleaved to yield a 86 aa mature protein (1, 2). EG-VEGF is expressed in multiple tissues including the gastrointestinal (GI) tract and steroidogenic glands (testis, ovary, placenta and adrenal glands). EG-VEGF has been shown to potently stimulate the contraction of GI smooth muscle. In addition, EG-VEGF is a tissue-specific angiogenic factor that exhibits biological activities similar to that of VEGF on select cells. It induces the proliferation, migration, and fenestration in cultured endocrine gland-derived capillary endothelial cells. EG-VEGF binds to and activates two closely related G protein-coupled receptors, EG-VEGF/PK1-R1 and EG-VEGF/PK2-R2 (3, 4). Activation of the receptors leads to stimulation of phosphoinositide turnover and activation of p44/p42 MAP kinase signaling pathways.
- Li, M. et al. (2001) Mol. Pharmacol. 59:692.
- LeCouter, J. et al. (2001) Nature 412:877.
- Lin, D. et al. (2002) J. Biol. Chem. 277:19276.
- Masuda, Y. et al. (2002) Biochem. Biophys. Res. Commun. 293:396.
Product Datasheets
Citations for Human EG-VEGF/PK1 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
2
Citations: Showing 1 - 2
Filter your results:
Filter by:
-
Up-regulation of endocrine gland-derived vascular endothelial growth factor but not vascular endothelial growth factor in human ectopic endometriotic tissue.
Authors: Lee KF, Lee YL, Chan RW, Cheong AW, Ng EH, Ho PC, Yeung WS
Fertil. Steril., 2009-01-09;93(4):1052-60.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-Fr -
Endocrine gland-derived vascular endothelial growth factor stimulates proliferation and tube formation in human uterine microvascular endothelial cell through the mitogen-activated protein kinase but not through the Akt pathway.
Authors: Lee YL, Chan YL, Chow WN, Ng EH, Lee KF, Yeung WS, Ho PC
Fertil. Steril., 2008-06-20;91(5):2163-71.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human EG-VEGF/PK1 Antibody
There are currently no reviews for this product. Be the first to review Human EG-VEGF/PK1 Antibody and earn rewards!
Have you used Human EG-VEGF/PK1 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
